Contagion Editorial Team

This past week has been extremely busy in infectious disease with a lot of vaccine news that could impact young children. In addition, GSK reported on its phase 3 study on its RSV vaccine for seniors.

The FDA VRBPAC votes to recommend mRNA vaccines in youngest children; WHO moves to rename monkeypox; Anthony Fauci is diagnosed with COVID-19; and Pfizer stops recruiting for a Paxlovid trial.

GSK’s Priorix MMR vaccine received the federal agency’s approval which was based from data of 6 clinical trials evaluating its safety.

The White House coronavirus response coordinator said vaccines for children under 5 could potentially begin on June 21.

This is the first test authorized for all 3 viruses and is over the counter.

Here is a rundown of the most popular stories we covered this past week.

Here is a rundown of the most popular stories we covered this past week.

Check out the important stories we covered this week.

The company’s filing for its NVX-CoV2373 vaccine is based off data from 2 large clinical trials.

Pfizer CEO Albert Bourla made the announcement in an interview.

The recall involves 2 lots of 100 mg of remdesivir for injection to the user level.

The agency said the 2 monoclonal antibodies could be used to treat mild to moderate COVID-19 in all younger pediatric patients, including newborns.

Highlights from the sessions of the World Anti-Microbial Resistance Congress 2021 included addressing the global threat for AMR and looking at real world data and real world evidence to deter resistance.

The therapy can be used for the treatment of invasive candidiasis.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

The company announced the Emergency Use Authorization (EUA) for use with its Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

A small subset of people living with HIV (PLWH) can naturally suppress the virus without medication.

The antibody profile in the blood of patients who have had the virus is extremely variable and this may modify the response to the treatment.

The shot will be its NanoFlu/NVX-CoV2373 vaccine using the company’s Matrix-M adjuvant platform.

FluGen announced its vaccine candidate, Bris2007 M2SR, induced neutralizing antibodies against infection and illness following a challenge with an antigenically distinct virus.

This therapy becomes the first single-dose infusion to treat acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.

In the second installment of an interview, members of the FlowMetric Life Sciences' leadership discuss how their technology might aid possible COVID-19 vaccine booster shots, how immunocompromised patients respond to vaccines, and other vaccines where their platform may be used.

FlowMetric, Inc., discusses its VaxEffect, an immune monitoring platform and how it can be used to measure COVID-19 vaccine responses.

The company’s mRNA-1010 is a seasonal influenza vaccine candidate that is targeting A H1N1, H3N2, influenza B Yamagata, and Victoria lineages.

The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.

This event will be a free, virtual event in July with expert speakers and survivors.

The organizations set out 3 recommendations for initial and recurrent C diff treatment.

Investigators looked at data from 3 analyses showed a reduction in mortality was observed across a spectrum of baseline oxygen requirements, at different timeframes, over the course of the pandemic, and in various geographies.

Paratek’s omadacycline (Nuzyra) is granted approval for an oral-only dosing regimen in adults.

The European Union (EU) agrees to look at easing restrictions for travelers from outside the continent, depending on vaccine or country status.